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1-leparin and heparin analogs prevent the binding of immune complexes
containing nucleosomal antigens to the GEM and delay nephritis in
MRLII mice. M. Ci. van Bruggen, C. Kramers, M.N. Hylkema, R.J. T.
Smeenk, G.WK van Dedem, and J.H.M. Berden, Department of Nephrology,
University Hospital Nijmegen, Nijmegen, Department of Autoimmune Dis-
eases, CLB, Amsterdam, and Diosynth By, Oss, The Netherlands. Recently,
we found that monoclonal anti-nucleosonie antibodies (mAbs) complexed
to nucleosomal antigens can bind to DNA and to heparan sulfate (HS) in
vitro and are able to bind to the GBM in vivo in a rat renal perfusion
system, whereas non-complexed mAbs do not bind. Heparin was able to
prevent the binding of these complexed mAbs to DNA and HS in vitro and
to the rat GBM in viva. When nucleosome/anti-nucleosome immune
complexes are injected intravenously (i.v.) into BALBIc mice, GBM
binding is observed. Pretreatment with heparin subcutaneously could
prevent this binding. Also, heparin analogs devoid of anticoagulant activity
could prevent binding of complexed anti-nucleosome antibodies in vitro
and in viva. We performed a therapeutic trial, testing the effect of heparin
(H) and two heparin analogs (N-desulfated acetylated heparin (DSA-H)
and low molecular weight N-desulfated acetylated heparin (LMW-H) on
the development of albuminuria in MRL/I mice (N = 15 per group).
Treatment was started at an age of 8 weeks and the dose given was 50 g
daily. In all three experimental groups albuminuria was significantly
delayed (P < 0.05). In the table the percentage of mice developing
albuminuria >1000 rg/18 hours is given.
Age in weeks
12 14 16 18 20
PBS 0 6 13 40 60
H 0 0 13 13 13
DSA-H 0 0 7 7 14
LMW-H 0 0 0 0 6
Since delayed type hypersensitivity and the antibody response to a nominal
antigen were not influenced by this treatment, we conclude that this effect
was not due to immunosuppression. We conclude that interaction of
heparin and heparin analogs with HS reactive immune complexes con-
taining nucleosomal antigens prevents the binding of these immune
complexes to the GBM and delays nephritis in MRL/I mice.
Heparan sulfate proteoglycans produced by glomerular visceral epithe-
hal cells inhibit the proliferative effect of basic fibroblast growth factor on
mesangial cells. N.F. van De4 NAM. Verhagen, J. T Tamsma, J. van der
Born, J.H.M. Berden, J.A. Bruijn, MR. Daha, and F.J. van der Woude,
University Hospitals Nijmegen and Leiden, Departments of Endocrinology,
Pathology, and Nephrology, Nijmegen and Leiden, The Netherlands. Me-
sangial expansion is an important hallmark of diabetic nephropathy. It has
been postulated that the decrease of glomerular heparan sulfate proteo-
glycan (HSPG) observed in diabetic nephropathy is important in this
respect, since HSPG could inhibit mesangial proliferation and matrix
production. Basic fibroblast growth factor (bFGF) may induce prolifera-
tion and extracellular matrix production in mesangial cells. It has been
described that heparan sulfate is necessary for the receptor signaling of
bFGF. We studied the interaction between glomerular HSPG and bFGF
to see if the interaction with bFGF might explain the negative autoregu-
latory effects of HSPG. We cultured human adult mesangial cells until
confluence and subsequently stimulated with 10 ng/ml recombinant bFGF
for 24 hours. 3H-thymidine (1 mCi/mi) was added for 6 hours and
harvested. bFGF induced a 4—6 fold increase in proliferation compared to
cells cultured under control conditions (DMEM + 0.5% A FCS). Gb-
merular HSPG isolated from human kidneys induced a significant inhibi-
tion of this mitogenic effect. Furthermore, we isolated HSPG from cell
media and cell extract of cultured human adult glomerular visceral
epithelial cells (GVEC) using two anion exchange columns and a superdex
HR200 HPLC gelfiltration column. HSPG obtained from both cell media
and cell extract of these cells inhibited the proliferative effect of bFGF on
mesangial cells significantly. Heparitinase and nitrous acid treatment of
these HSPG fractions reversed this inhibition. We conclude that heparan
sulfate produced by GVEC inhibits the effect of bFGF on mesangial cells.
Since heparan sulfate production by GVEC decreases under high glucose
conditions, our findings suggest that a decrease in glomerular heparan
sulfate is of importance for the observed mesangial expansion in diabetic
nephropathy.
Anti-nucleosome antibodies complexed to nucleosomal antigens bind to
cell surfaces and are internalized. Post-fixation migration of these
antibodies leads to in vivo ANA. C. Kramers, M.C.J. van Bniggen, G.P.M.
Rijke, H.B.P.M Dijkman, H. Croes, J. Fransen, R.J. T Smeenlc and J.H.M
Berden, Departments of Nephrology, Pathology and Celbiology, University
Hospital, Nijmegen, and Department of Autoimmune Diseases, CLB, Am-
sterdam, The Netherlands. It has been suggested that binding of anti-DNA
antibodies to cell surfaces, subsequent internalization, and nuclear binding
(in vivo ANA) have pathophysiological consequences in SLE and may
contribute to the development of nephritis. We have found previously that
pathogenic anti-DNA antibodies can bind to heparan sulfate in renal
basement membranes after complexing with nucleosomal antigens. Since
it was found that nucleosomes can also mediate binding to cell surfaces
and subsequent internalization, we hypothesized that in vivo ANA is a
property of antibodies bound to nucleosomal antigens. We studied three
anti-nucleosome mAbs which exhibit in vivo ANA in immunofluorescence
(IF) when the hybridoma producing the mAb is inoculated intraperitone-
ally in mice. These antibodies complexed to nucleosomal material were
injected intravenously (iv.) in mice. After this injection in IF, in viva ANA
was observed, whereas injection of pure mAbs did not cause an in viva
ANA. In additional experiments with lymphoid cells we found that
complexed antibodies bound to cell surfaces and were subsequently
internalized in cytoplasmic vesicles, whereas pure non-complexed mAbs
did not bind to cell surfaces and did not enter the cytoplasm. However,
these complexed mAbs did not reach the nucleus in living cells. Because
of this discrepancy, the in viva experiments were repeated, a small part of
the kidney was snap frozen in liquid N2, fixed with acetone and studied in
IF, whereas the rest was fixed in viva by perfusion with PLP and studied in
both IF and immunoelectron microscopy (IEM). After the former proce-
dure ANA was observed; however, after PLP perfusion fixation nuclear
binding was not observed. By IEM antibodies were identified in cytoplas-
mic lysosomes. In conclusion: anti-nucleosome antibodies complexed to
nucleosomal antigens can bind to cell surfaces and are transported into the
cytoplasm. Binding to nuclei is due to a post-fixation artifact. In viva ANA
found in patients might be due to this phenomenon. It is questionable,
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therefore, whether this in vivo ANA has any pathophysiological signifi-
cance.
Impaired endothelial function in patients with nephrotic range protein-
uria (NS). E.S.G. Stroes, J.A. Joles, P.C. Chang, HA. Koomans, and TJ.
Rabelink, Department of Nephrology, Academic Hospital Utrecht, Leiden,
The Netherlands. Proteinuria is associated with increased cardiovascular
morbidity and mortality. Release of nitric oxide by the endothelium has
been advanced as an important defense mechanism against vessel wall
damage. In the present study we therefore tested the hypothesis that
proteinuria is associated with endothelial dysfunction using venous occlu-
sion plethysmography of the forearm. We infused L-NMMA (8 jsmol/
mm), to inhibit basal nitric oxide (NO) production, serotonin (5-HT) (0.1,
0.3 and 1.0 ng/kg/min) to specifically stimulate NO release, and nitroprus-
side (SNP) (1, 10, 30 and 100 nglkg/min) as an endothelium-independent
vasodilator in the brachial artery of 9 NS (>3.5 g/24 hr) and normal renal
function (creatinine 83.1 8.7 smol/liter). Control experiments were
performed in 8 patients with active glomerulonephritis (GN) hut normal
renal function (creatinine 79.4 5.4 jrmol/liter) and 10 healthy volunteers
(C). The intra-arterial infusions were repeated after local administration
of excess L-arginine (1 imol/kg/min), the substrate for NO synthase.
Upon 5-HT infusion forearm vascular resistance (FVR) in NS decreased
by 40% 5, which was significantly lower than in GN (56% 3; P < 0.05)
and C (55% 3; P < 0.05). The calculated concentration, causing a 25%
decrease in FVR (EC25; expressed as —log molarfl, was significantly
higher in NS compared to GN and C (—8.26 0.16 vs. —8.76 0.08 and
—8.81 0.11; P < 0.01). The maximal decrease in FVR after SNP was not
different between the groups (respectively 84% 2, 84% 3 and 84%
2; NS). The impaired 5-HT-induced vasodilation could be attributed to a
defect in NO production, since L-NMMA almost completely prevented
serotonergic vasodilation. In contrast, inhibition of basal nitric oxide
activity by L-NMMA was not significantly different between these groups
(FBF decreased by 30% 4, 39% 4 and 37% 2; P =0.15). The defect
in agonist-induced NO release could not be explained by decreased
substrate availability, as infusion of excess L-arginine did not improve
vasodilation. The nephrotic subjects also had increased lysophosphatidyl-
choline content in the low-density lipoprotein fraction, which has been
shown to interfere with Gi protein-dependent signal transduction path-
ways, including 5-HT-induced vasodilation. In conclusion, nephrotic sub-
jects demonstrate an impaired serotonin-induced nitric oxide release. This
impaired vasodilatory response to serotonin, and thus decreased release
and/or activity of nitric oxide, may imply a defective endothelial defense
mechanism against vascular injury, and thus a major cardiovascular risk
factor.
Videomicroscopic characterization of afferent and efferent arteriolar
responses to angiotensin I and angiotensin II. P.M. ter Wee, H. Forster, and
M. Epstein, Nephrology Section, VAMC and University of Miami, and
Department of Nephrology, Free University Hospital Amsterdam, Amster-
dam, The Netherlands. Utilizing a computer-assisted videomicroscopic
technique, the effects of angiotensin I (Ang 1) and Angiotensin II (Ang II)
were investigated in isolated perfused hydronephrotic kidneys. In group 1,
the long-term effect of Ang 11(0.3 nM) on afferent (AA) and efferent (EA)
arterioles was studied. In group 2, the microvascular effects of adding Ang
1(0.3 nt and 1.0 nM) were assessed. In group 3, kidneys were pretreated
with the ACE-inhibitor Trandolaprilat (TRAN; 10 tLM), followed by the
addition of Ang Tin the same doses as group 2. At the end of this study,
Ang 11(0.3 nat) was added to assess the specificity of TRAN. In response
to Ang II, AA (N = 17) manifested a persistent constriction (at 15 mm
—35% SE 2.3%; at 90 mm —32.0% SE 1.8%). In contrast, EA (N =
11) manifested a biphasic response: an initial constriction of —38.5%
3.3% at 15 minutes was followed by a gradual dilation (at 90 mm EA
diameter averaged — 16.5% 4.3% compared to baseline). Ang I induced
an AA constriction (N = 24)of —14.7% 2.7% at 0.3 nat and —27.3%
2.4% at 1.0 nat. Ang I-induced EA constrictions (N = 19) were —10.2
1.9% and —20.9 2.4%, respectively. Pretreatment with TRAN attenu-
ated the AA constriction (N = 23) at 0.3 nM Aitg I (—6.5 1.2%; P <
0.025 vs. Ang I alone) and at 1.0 nM Ang I (—12.7 1.4%; P < 0.001 vs.
Ang I alone). Subsequent addition of Ang II induced a constriction of
—39.9 1.8%. In EA (N = 13) pretreatment with TRAN completely
prevented the Ang I-induced constriction (0.4 1.3% at 0.3 nM Ang I,
—1.2 1.2% at 1.0 nat Ang I; both P < 0.001 vs. Ang I alone). After the
subsequent addition of Ang II, EA constricted by —27.8 3.3%. In
conclusion, we demonstrated that AA respond to Ang II with a persistent
vasoconstriction over time, whereas EA manifest a biphasic response. In
addition, our observation that the ACE-inhibitor TRAN blunted the Ang
I-induced AA constriction and prevented the Ang I-induced EA constric-
tion, indicates that tissue-ACE participates in the local control of the renal
microcirculation.
Increased transcapillary escape rate of albumin (TERIb) and regional
clearance of albumin (RCIb) in long-term albuminuric diabetic rats. J.
van den Born, A.A. van Kraats, M.A.H. Bakker, and J.H.M. Berden,
Department of Nephrology, University Hospital Nijmegen, Nijmegen, The
Netherlands. To investigate whether the development of albuminuria in
experimental diabetes is a symptom of a more generalized vessel wall
leakage, we measured the TERaIb and the RCaIh in several tissues one year
after streptozotocin-induced diabetes in male Wistar-Munich rats. To this
end 7 diabetic and 7 control rats were anesthetized with mactin and
received iv. 2 jsCi '251-albumin and 10 jsCi nCrlabeled red blood cells.
The TERaIb was calculated from the disappearance rate of 125I-albumin
from the circulation, from 10—40 minutes after iv. injection. Since 5tCr
red blood cells will not disappear from the circulation, this tracer enabled
us to calculate the amount of extravascular albumin and RCa15 in the
individual tissues. Results are shown in the table below; differences were
tested in the unpaired Mann Whitney U-test.
Parameter Diabetic rats Control rats P value
TERaIb %/hr 15.6 2.6 13.3 1.7 0.02
RC,jh jd/g mm
kidney 2.04 0.34 2.00 0.15 NS
heart 1.91 0.34 1.11 0.13 0.0006
liver 1.36 0.11 1.15 0.12 0.007
lung 1.48 0.23 1.95 0.16 0.0012
skin 0.41 0.07 0.40 0.19 NS
muscle 0.11 0.03 0.08 0.02 0.04
aorta 2.26 0.72 1.35 0.24 0.04
Albuminuria mg/24 hr 31.7 10.8 2.2 1.5 0.0006
MAP mm Hg 118± 12 135 0.003
Vascular volume/100 g body wt, ml 6.42 0.29 4.65 0.28 0.0006
Blood glucose mmol/liter 25.2 2.2 5.0 0.3 0.0006
These data clearly show that in diabetic rats an increased urinary albumin
excretion is associated by increases in TERa15 and RCa15 in most, but not
all, tissues. The fact that the TERaIb did not correlate with MAP, vascular
volume or blood glucose, suggests that intrinsic capillary wall properties,
rather than hemodynamic factors, are responsible for the increased
vascular leakage of albumin in diabetic rats. Whether this is related to
alterations of heparan sulfate in the vascular wall is under current
investigation.
Intervention in experimental anti-MPO associated crescentic glomer-
ulonephritis by monoclonal antibodies against adhesion molecules. AC.
Muller Kobold, J. W Cohen Tervaert, PA. KIok, and C. G.M. Kallenbeg,
Department of Clinical Immunology and Pathology, University Hospital
Groningen, Groningen, The Netherlands. Renal failure frequently occurs in
patients with anti-MPO associated systemic vasculitis. Histopathologically
it is manifested as necrotizing crescentic glomerulonephritis without
immune deposits. Recently, Brouwer et al developed a model of anti-
MPO associated glomerulonephritis in the Brown Norway (BN) rat. To
assess the possibilities of mitigating renal damage by blocking adhesion
molecules, we evaluated the effects of mouse monoclonal antibodies to rat
KAM-1 (1A29) and rat CD18 (WT3) in this model. Distribution and
half-life in the rat of 1A29 were determined by imaging techniques. For
WT3, half-life was determined by Facs analysis. For both monoclonals
half-life amounted to 24 hours. Next, BN rats were immunized with
human MPO and subsequently disease was induced by perfusing the left
kidney with products of activated granuloeytes, that is lytic enzymes, MPO
and its substrate H202. To study the effect of blocking adhesion molecules,
rats were treated with 1A29 and WT3 or with 1A29 alone, whereas control
rats were treated with an irrelevant monoclonal antibody (MOC31). Rats
were injected every 2 days (1 mg/rat of each Moab), starting 2 days before
disease induction. The experiment was terminated 5 days after disease
induction. The following results were obtained: Urine, collected 24 hours
1364 Abstracts
after disease induction, of rats treated with MOC3 I or I A29 alone
contained red cell casts, while rats treated with both lA29 and WT3 had
normal urine sediments. At 5 days after disease induction, only a few
lesions were observed in the kidneys of rats treated with the combination
of 1A29 and WT3, while MOC3I treated rats had developed creseentic
glomerulonephritis. No significant differences in cellular infiltrate could be
found between 1A29 treated rats and MOC31 treated rats. In conclusion,
blocking both ICAM-l and CD18 appears to mitigate damage due to
anti-MPO associated glomerulonephritis, while blocking ICAM-I alone
does not.
Deficient mucosal and systemic immune respons in patients with IgA
nephropathy after repeated nasal immunization with cholera toxin sub-
unit B. J. W de Fjter, J. W Eijgenraam, CA. Braam, J. Holmgren, A. W.L.
van de Wall Bake, MR. Daha, and L.A. van Es, Department of Nephrology,
University Hospital Leiden, The Netherlands, and Department of Medical
Microbiology and Immunology, Goteborg, Sweden. Mesangial deposition of
JgA is the hallmark of patients with primary IgA nephropathy (IgAN). The
role of increased IgA plasma levels, circulating IgA-containing immune
complexes and the mechanisms leading to mesangial deposition are still
unclear. The abnormalities in the IgA immune system are restricted to the
IgAl subclass and there is accumulating evidence that the IgAl in the
mesangium may be bone marrow derived. The clinical association of
upper respiratory tract infection with exacerbation of the disease and the
results of previous immunization studies in IgAN lead to the hypothesis of
a dysregulated "mucosa-bone marrow axis." Mucosal immunization with
nonreplicating antigens generally induces both a local immune response at
the site of immunization and a disseminated response at locations remote
from the site of antigen encounter when mucosa associated lymphoid
tissues are rechallenged. Infection with a replicating antigen also leads to
a systemic immune response manifested by the presence of plasma
antibodies. Cholera toxin subunit B (CTB) has been shown to induce not
only a strong mucosal IgA response but also serum IgA (and IgG)
antibodies. In this context we investigated the mucosal and systemic
immune response in 12 patients with IgAN and 18 healthy volunteers after
3 subsequent intranasal immunizations with 0.33 mg of recombinant CTB
(interval: two weeks). Simultaneous parenteral immunization with keyhole
limpet hemocyanin (KLH) served as control. Mononuclear cells from
peripheral blood (day: 0, 7, 21, 35, 42) and bone marrow aspirate (day 42)
were isolated, and the 1gM, IgG, IgA, IgAl and IgA2 antibody secreting
cells (antigen-specific and non-specific) were enumerated as spot forming
cells (SFCI1OE6) using the ELISPOT technique. Body fluids (plasma,
nasal wash, saliva) were assessed for antigen-specific antibodies in ELISA.
Statistical analysis was performed on logarithmically transformed data
using a two-way analysis of variance with repeated measurements, fol-
lowed by Scheffe's procedure for post hoc comparison. There was a
significant immune response after immunization with both antigens in
PBMC's and plasma for all isotypes tested (P < 0.0001). PBMC's from
patients with IgAN showed a significantly lower number of CTB-spccific
IgA and IgAl secreting cells after the first (P < 0.005, respectively P <
0.0001), the second (P < 0.005, respectively P < 0.001) and the third
immunization (P < 0.05, respectively P < 0.05). The CTB-specific IgA and
IgAl plasma titers were also significantly lower in IgAN after the second
and third dose of CTB (P < 0,05). There was no detectable specific
mucosal immune respons in IgAN, reaching significance with controls
after the third dose P < 0.0005). The immune response after parenteral
immunization with KLH was not different between patients and controls.
At day 42 there was a significant correlation between the number of IgA
and IgAl SFC/10E6 cells (r = 0.67, P < 0.005, respectively r = 0.76, P <
0.001) and the number of CTB-specifie IgA and IgAl SFC/10E6 (r 0.68,
P < 0.001, respectively r 0.62, P < 0.001) in the bone marrow with the
respective concentration or titer of IgA or IgAl in plasma. Two important
conclusions can be made from the present study. First, our results support
the existence of a mueosa-bone marrow axis in humans. Secondly, there is
no systemic hyperresponsiveness in IgAN after mucosal immunization
with CTB. In the population studied, patients with IgAN exhibit a
deficient mucosal and systemic IgAl immune response, despite the
repeated challenge with a strong mucosal immunogen. No apparent
dysregulation of this axis in IgAN was found in this study. In theory, this
may implicate that patients with IgAN depend upon more frequent or
prolonged antigenie encounter before adequate immunity at mucosal sites
and systemic memory develops or that the type of antigen and its
dependence on T cell help determine the ensuing IgA response.
Vasoactive effects of arginine vasopressin in healthy subjects and
patients with a V2 receptor defect. A.F. van Lieburg, V VA.M. Knoers,
L.A.H. Monnens, T. Thien, and P. Smits, Department of Pediatrics, Human
Genetics and Internal Medicine, University Hospital Njmegen, Nijmegen,
The Netherlands. Studies assessing the vasoactive effects of arginine
vasopressin (AVP) have yielded contrasting results, varying among spe-
cies, between in vitro and in vivo studies, and among different vascular
beds. Experiments in the human forearm vascular bed suggest that low
dosages of AVP induce vasoconstriction, whereas higher dosages induce
nitric oxide (NO)-mediated vasodilation. To elucidate the role of vaso-
pressin type I (Vi) and 2 (V2) receptors in this biphasic response, we
investigated the vasoactive effects of AVP and 1-desamino-8-D-arginine
vasopressin (DDAVP) in healthy volunteers as well as in patients with
nephrogenic diabetes insipidus (NDI) with a proven V2 receptor gene
defect. Venous occlusion plethysmography was used to assess the forearm
blood flow (FBF) response to infusion of (DD)AVP into the brachial
artery, both in the absence and presence of the NO-synthase inhibitor
L NMMA (0.1 mg/min/dl). DDAVP (5—10—20 nglmin/dl) induced a
dose-related increase of FBF from 2.3 0.7 up to 10.3 2.5 ml/min/dl in
healthy subjects (P < 0.01, N = 7), hut did not affect FBF in ND! (1.3
0.3 to 1.3 0.4 ml/min/dl, N = 3). In 2 healthy subjects, 7 incremental
dosages of AVP (0.25 to 12.0 ng/min/dl) induced an initial decrease of
FBF from 1.3 to 1.1 mi/min/dI, followed by a gradual increase to 3.1
mI/min/dI. The same dose range of AVP resulted in a gradual but
progressive decrease of FBF from 1.2 to 0.4 mI/min/dI in NDI (N = 1). In
healthy volunteers, infusion of L-NMMA reduced FBF from 2.3 0.5 to
1.6 0.2 (N = 10, P 0.05). The increase in FBF induced by DDAVP (10
ng/min/dl) was significantly reduced by L-NMMA (5.7 1.0 vs. 4.2 0.8
ml/min/dl, N = it), P < 0.01). We conclude that in humans, AVP-induced
vasoconstriction is completely mediated by Vi receptor stimulation,
whereas vasodilation induced by DDAVP or high dosages of AVP, is
completely mediated by V2 receptor stimulation. This V2 receptor
mediated vasodilation is at least partially mediated by release of NO.
The intracellular redox status modifies susceptibility to mercuric
chloride-induced T cell activation. J. Aten, N. Claessen, MA. Chand, and
J.J. Weening, Department of Pathology, University of Amsterdam, Amster-
dam, The Netherlands. In rodents, HgCI2 can induce T cell activation
leading in a genetically restricted way to either Thi-initiated immune
suppression or Th2-dependent systemic autoimmunity. Since in an early
stage of the syndrome HgCl7-indueed T cell activation is independent of
MHC class II antigens, non-antigen-specific ways of cell activation seem to
be involved in this process. The cellular response to HgCI2 was examined
using the murine T cell hybridoma 2B4.11 and human Jurkat and PBL T
cells. HgCI, was found to cause Ca2 influx as well as mobilization of Ca2
from intracellular stores, to induce generation of free radicals, and to
diminish intracellular glutathione (GSH) levels, the latter being accom-
panied by induction of apoptosis. Upon 24 hour incubation, the surviving
cells displayed strongly increased GSH levels. HgCI2-indueed generation
of oxidative stress was prevented by intracellular chelation of Ca2t
HgCI2-induced increase of both intracellular Ca2 and free radicals was
prevented by the reducing agent DTT; GSH, which is relatively cell
membrane impermeable, was less effective. Neither DTT nor GSH
prevented ionomycin-induced Ca2 influx and oxidative stress. HgCl2
stimulated the production of IL-4, but not of IL-2, by 2B4.1l cells.
Inhibition of intracellular GSH synthesis enhanced the susceptibility to
HgCl2-induced cell death and increased HgCI2-induced IL-4 production.
Thus, HgCl2 can induce cell activation leading to cytokine production
and/or apoptosis. Susceptibility to both HgCl2-induced cell activation and
HgCI2-induced cell death seems to be dependent on the intracellular
redox status.
Differential changes in T-lymphocyte adhesion molecule expression
during induction of immune dysregulation by mercuric chloride. A. Roos,
N. Claessen, J.J. Weening, and J. Aten, Department of Pathology, University
of Amsterdam, Amsterdam, The Netherlands. Injection of HgCI2 induces a
CD45RCk Tu2-dependent autoimmune syndrome in Brown Norway
(BN) rats, involving glomerulopathy and proteinuria, and a TH1-depen-
dent generalized immune suppression in Lewis rats. The induction of
HgCI2-induced autoimmunity is associated with MHC class Il-indepen-
dent T-T-lymphocyte interactions, which may involve altered expression
or function of adhesion molecules on HgCI2-exposed T-lymphocytes.
Therefore, expression of T-lymphocyte adhesion molecules was studied in
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BN rats (N = 7) and Lewis rats (N = 6) during induction of immune
dysregulation by HgC12. Tn-color flow cytometly was performed on day 4
on peripheral lymph node cells of rats treated with HgCI2 or H20.
Following injection of HgCI2, numbers of ICAM-1 * cells in CD4 small
cells were increased by 57% and 21% in BN and Lewis rats, respectively.
CD4 T-cells from HgC12-injected BN rats showed higher LFA1 expres-
sion (+ 44%), increased fractions of CD45RCO cells (+ 14%), and
increased fractions of OX40 cells (+ 78%) within CD45RC'° but not
within CD45RC5 cells. In addition, CD45RCIO blast cells of these rats
showed modified expression of VLA4 (+ 33%) and CD43 (— 21%). These
changes were not seen in Lewis rats. Numbers of CD26 cells were
increased in CD4±CD45RCI0 blast cells of both HgCI2-treated BN rats (+
290%) and Lewis rats (+ 88%). In contrast to BN rats, HgCI2-treated
Lewis rats showed an increase in the fraction of CD45RC5 cells in their
CD4 blast cell population (+ 29%). However, these cells did not show
any abnormality in adhesion molecule expression. In summary, our results
indicate that HgCI2-injection induces altered adhesion molecule expres-
sion predominantly in CD4±CD45RCIO cells of BN rats. In CD4 cells of
Lewis rats we only detected alterations in expression of ICAM-1 and
CD26, and these changes were much less pronounced than those observed
in BN rats. The differential effects of HgCI2 on adhesion molecule
expression in BN and Lewis rats may play a role in the immune
dysregulation syndromes induced by HgCI2 in these rat strains.
Anti-Thy-i monoclonal antibodies (MAb) induce apoptosis of cultured
rat glomerular mesangial cells (GMC). T Sato, J.G.A. van Dishoom,
W.E.M Schroeijers, T. W.J. Huizinga, C.P.M. Reutelingsperger, L.A. van Es,
and MR. Daha, Department of Nephrology, University Hospital Leiden,
Leiden, and Department of Biochemistty, University of Limburg, Limburg,
The Netherlands. Apoptosis is a counteracting regulatory mechanism
against undesired cell proliferation. Anti-Thy-I nephritis is a model of
mesangial proliferative glomerulonephritis. It has been reported that
histological changes in Thy-i nephritis are associated with the occurrence
of apoptotsis. In the present study, we have investigated whether anti-
Thy-I MAb (ER4) is able to induce apoptosis of rat GMC in vitro.
Quiescent rat GMC were co-cultured with RPMI 1640 containing 0.5%
FCS alone, medium containing IgG2a anti-Thy-I MAb, its F(ab')2
fragments or irrelevant control MAb, and were assessed for apoptosis
qualitatively and quantitatively. In morphological studies with Hoechst
33258 stain, distinct nuclear fragmentation was observed with IgG2a
anti-Thy-i MAb and its F(ab')2 fragments. The effect was time- and
dose-dependent. Apoptosis of cultured rat GMC also was detected by the
dislocation of negatively charged phospholipid, phosphatidylserine, from
the inner to the outer leaflet of the membrane. This method is a sensitive
method for the measurement of apoptosis. Anti-Thy-i MAb and its
F(ab')2 fragments induced apoptosis of rat GMC in a time- and dose-
dependent fashion, while medium alone, irrelevant control MAb and its
F(ab')2 fragments displayed no significant apoptosis of cultured rat GMC.
Upto 29% and 34% of cultured rat GMC displayed apoptosis with 1 j.rg/ml
of IgG2a anti-Thy-I MAb or its F(ab')2 fragments, respectively. Apopto-
sis was finally analyzed by gel electrophoresis. DNA extracts from cells
co-cultured with IgG2a anti-Thy-i MAb or its F(ab')2 fragments demon-
strated typical internucleosomal DNA fragmentation. Taken together, the
results demonstrate for the first time that IgG2a anti-Thy-I MAb (ER4) is
able to induce apoptosis of cultured rat GMC. The Thy-i antigen on rat
GMC therefore functions as one of the molecules regulating cell death
and thereby determines the degree of mesangial alteration.
Infection of human renal mesangial cells with cytomegalovirus in vitro
affects the production of complement components in a differential fash-
ion. J.J. Timmerman, M.F.C. Beersma, D.J. van Gijlswijk-Janssen, F.J. van
der Woude, L.A. van Es, W.M. Spaan, and M.R. Daha, Department of
Nephrology and Virology, University Hospital Leiden, Leiden, The Nether-
lands. Human cytomegalovirus (HCMV) infection is widely spread in the
human population. In individuals with deficient cell-mediated immunity
(i.e. transplantation or AIDS patients) primary or secondary CMV
infection leads to severe illness. In vitro infection of renal mesangial cells
(MCs) with CMV results in an increased expression of MFIC class I
antigens on the cell surface of MCs, whereas MHC class II antigen
expression is not affected. A number of complement components, namely
factor B, C4 and C2, are encoded by the MHC class III region, positioned
in between the MHC class I and II region. Previously, we showed that
regulation of factor B synthesis by a number of defined cytokines,
resembles MHC class I antigen expression, whereas the regulation of C4
synthesis resembles MHC class II antigen expression. In the present study,
we investigated the effect of CMV infection of renal MCs on the
production of the MHC class III encoded complement factors. First, a
number of adult and fetal MCs were infected with CMV. While all adult
MCs were susceptible to infection by CMV, fetal MCs were not infected
by CMV. Next, we investigated the complement production of CMV-
infected MCs. Factor B and C2 protein production was not detectable in
control cells, but in the CMV infected cell populations an induction of
both factor B and C2 occurred up to 250 pg/mI and 15 ng/ml, respectively.
C4 synthesis was not detectable in both control and in infected cells.
However, we were able to detect C4 synthesized by MCs when they were
stimulated with IFN-y. By Northern blot analysis we observed an induc-
tion of factor B mRNA in CM V-infected MCs, whereas the mRNAs for
C2 and C4 were not detectable. RT-PCR analysis revealed induction of
both factor B and C2 mRNA in the infected cell populations. Production
levels of the regulator of the alternative pathway of complement, factor H,
both in control and infected cells was 30 ng/ml. The steady state levels of
factor H mRNA were not altered. CMV infection of the MCs resulted also
in an up-regulation of IL-6 synthesis, both at the protein and mRNA level.
In conclusion, we have shown that CMV infection of MCs resulted in an
up-regulation of factor B and C2 synthesis both at the protein and mRNA
level. Production of C4 and factor H was not affected by CMV infection.
None of the fetal MCs were infected by CMV, indicating that they
probably lack an (unknown) receptor for CMV on their cell surface.
Intrarenal injection of lipopolysaccharide in myeloperoxidase immu-
nized brown Norway rats. P. Heeringa, P.A. Kb/c M. G. Huitema, P.
Foucher, and C. G.M. Kallenberg, Departments of Clinical Immunology and
Pathology, University Hospital Groningen, Groningen, The Netherlands.
Necrotizing crescentic glomerulonephnitis (NCGN) associated with anti-
bodies directed against myeloperoxidase (MPO) is characterized by
fibninoid necrosis of the glomerular capillary wall, marked infiltration of
neutrophils and mononuclear cells, and paucity of immune deposits.
Recently, Brouwer et al developed an animal model for pauci-immune
anti-MPO associated NCGN in Brown Norway (BN) rats. This model is
dependent on a MPO directed immune response and the presence of
neutrophil lysosomal enzymes and H202 along the glomerular basement
membrane. The present study adresses the question whether local activa-
tion of neutrophils in the presence of an anti-MPO directed immune
response leads to the development of NCGN. For this purpose, BN rats
were immunized with human MPO (10 sg/rat) in complete Freunds
adjuvant (CFA) or with control solution in CFA. Sera were screened for
the development of antibodies directed against human and rat MPO by
ELISA and indirect immunoflourescence on ethanol fixed human and rat
neutrophils. Two weeks after immunization a single injection of lipopoly-
saccharide (LPS, 1 mg/kg) in PBS was given in the left renal artery. Rats
were sacrificed I and 7 days after injection and renal tissue was processed
for histopathology including immunofluorescence and immunocytochem-
istiy. BN rats immunized with human MPO developed a humoral response
against human MPO and, to a lesser extent, to rat MPO. One day after
LPS injection the number of intraglomerular neutrophils and monocytes
was higher in the MPO immunized rats compared to control immunized
rats. At day one, no intraglomerular immunoglobulin depositions could be
detected in both groups. Seven days after LPS injection the number of
intraglomerular neutrophils decreased in both groups, although still more
neutrophils were found in MPO immunized rats. At this time point more
intraglomerular monocytes were found in both groups compared to day 1
and more monocytes were found in MPO immunized rats compared to
control immunized rats. However, inflammatory lesions charactenisitic for
anti-MPO associated NCGN had not developed.
Systemic and renal hemodynamic effects of tertatolol and atenolol in
renal transplant recipients on cyclosporine A. A.J. W. Bra nten, LB.
Hilbrands, H. W. van Hamersvelt, RAP. Koene, and F. Th.M. Huysmans,
Department of Nephrology, University Hospital Nijmegen, Ntjmegen, The
Netherlands. Cyclosponine A (C5A) contributes to hypertension after renal
transplantation. Probably this effect of CsA is largely mediated by aft'erent
renal vasoconstniction and is accompanied by decreases of RPF and GFR.
In this situation, the beta blocker tertatolol (Ten) could be of special
advantage since in hypertensive patients this drug has been proven to
reduce BP with a simultaneous increase of RPF and GFR. However, little
is known of the renal and antihypertensive effects of Ten and other beta
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blockers in patients on CsA. Therefore, in 12 hypertensive renal transplant
recipients (8 males, 4 females, mean age 45 11 years) treated with CsA
and a stable renal function 83 61 weeks after transplantation, we studied
the systemic and renal hemodynamic effects of Ter compared to atenolol
(At) and to a period without any antihypertensive drug. Native kidney(s)
were in Situ lfl all. Patients were treated during periods of 4 weeks with At
and Ter, respectively, separated by a wash-out period of 4 weeks. At the
end of each period BP (Dinamap), heart rate (HR), GFR, and RPF
(constant infusion of inulin and PAH, respectively) were measured.
Results are given in the table.
At Wash-out Ter
MAP, mm Hg 124 2' 132 4 125 2
HR, b/mm 54 3 65 3 55 2'
GFR, ml/min/1.73 m2 45 3 47 4 45 3
RPF, ml/min/l.73 m2 167 15 163 14 158 11
Mean SEM; "P < 0.05 compared to wash-out, MAP = mean arterial
pressure
Conclusion: Both At and Ter effectively reduced BP in patients on CsA.
Since both drugs did not have any influence on GFR and RPF, Ter but
also At can be safely used for the treatment of hypertension in renal
transplant recipients on CsA. Our data do not explain the lack of a renal
vasodilating effect of Ter in this specific group of patients.
Endogenous ACE inhibitors are present in rat cardiac and renal tissue
but not in aorta and serum. J. Koiter, G.J. Navis, P.E. de Jong, W.H. van
Gust, and D. de Zeeuw, GUIDE, University Hospital, Groningen, The
Netherlands. ACE inhibitor effects are reported to correlate with tissue
ACE activity rather than serum ACE. Thus, accurate measurement of
tissue ACE activity is of importance. However, pilot studies showed that
sample dilution interferes with detection of ACE activity. Since different
tissues require different sample dilution levels, both absolute activities and
ratios between the ACE activities of different tissues could be incorrect.
To establish this effect we measured ACE activity in serum, aorta, left
ventricle and kidney at seven dilutions. Tissues and serum were obtained
from male Wistar rats (N = 6). The ACE assay was performed with the
substrate Hip-His-Leu. Released hippurie acid was measured by HPLC
with UV detection. The initial sample dilution factor for serum, left
ventricle, kidney, and aorta was 1, 5, 5, and 10, respectively. Serum was
initially measured undiluted. ACE activity increased significantly with
increasing sample dilution in homogenates of both left ventricle and
kidney, but not in aorta and serum. The maximum left ventricle and kidney
ACE activity (both 250% of the initial value) was reached when the
samples were diluted 20 and 50 times, respectively. This in vitro dilution-
induced increase in ACE activity suggests competitive inhibition of ACE
by endogenous substances. This was confirmed by the fact that a known
quantity of added purified ACE was inhibited by left ventricle and kidney
homogenate: at 10% dilution, 49% and 36%, respectively. No inhibition of
added ACE was observed in serum. In conclusion, the presence of
eridogenous ACE-inhibitors in cardiac and renal tissue strongly affects the
measurement of ACE activity in tissue homogenates. For adequate
assessment of the ACE activity in these tissues a series of sample dilutions
is necessary. The (patho-) physiological role of these endogenous inhibi-
tors in viva remains to he established.
No effect of ranitidine on tubular creatinine secretion. J.G. van den
Berg, M. G. Koopman, and L. Arisz, Academic Medical center, Amsterdam,
The Netherlands. Oral cimetidine competitively inhibits tubular creatinine
secretion. We investigated the potential of oral ranitidine, another widely
used H2-receptor antagonist, to block tubular secretion of crcatinine,
when given in regular (300 mg) to maximum (1200 mg) daily doses. Tn 10
normal subjects (5 males and 5 females, age 21—24 years), standard
clearances of inulin and endogenous creatinine were simultaneously
measured from 10 am. to 6 p.m. Inulin was administered by continuous
infusion, starting at 8 am. After 2 hours equilibration, two 1.5 hour
clearances were measured without ranitidinc, followed by three clearance
periods after ingestion of a single dose ranitidine at 1 p.m. All subjects
participated in the first part of the study, when the effect of 300 mg
ranitidine was studied; 4 subjects who showed the highest tubular creati-
nine secretion also participated in the second part, 3 weeks later, when
1,200 mg ranitidine were administered. As expected, neither dose of
ranitidine caused a significant change in GFR, measured by inulin
clearance and expressed as ml/min/1.73 m2: mean (±sD) baseline GFR
was 128.7 (±20.3) versus 129.2 (± 19.5) after 300mg ranitidine, P 0.96;
in the 4 subjects who received 1,200 mg ranitidine 134.5 (±12.8),
respectively 137.7 (±11.1) ml/min/l.73 m2, P = 0.72. However, mean
plasma creatinine did not change either: 65.9 (± 8.4) /Lmol/liter before and
66.0 (±9.3) j.mol/liter after 300 mg ranitidine, P = 0.99; 59.0 (±3.4)
rmol/liter before and 58.5 (±2.0) mol/liter after 1,200 mg ranitidine.
Creatinine clearance (Cr) also remained unchanged [mean baseline Cr
was 148.5 (±20.3) ml/min/1.73 m2 vs. 149.1 (±20.3) after 300 mg raniti-
dine, P = 0.95 and 165.2 (± 26.8) before vs. 158.2 (± 16.0) after 1,200 mg
ranitidine, P = 0.67]. Consequently, ranitidine had no effect on the mean
creatinine relative to inulin clearance ratio [Ccr/Ci 1.18 (±0.10) before
and 1.17 (±0.09) after 300mg ranitidine, P = 0.81; baseline CCr/CI = 1.21
(±0.13) before and 1.16 (±0.13) after 1,200 mg ranitidine, P = 0.58]. We
conclude that a single oral dose of 300 to 1,200 mg ranitidine does not
inhibit tubular secretion of creatinine. This lack of effect could be due to
lower affinity of ranitidine for the transport carrier at the luminal tuhulus
membrane compared to cimetidine.
Cimetidine improves GFR estimation by the Cockcroft and Gault
formula. M.C.J. Jxkes, M.G. Koopman, B.A.C. van Acker, J.A. Weber, and
L. Arisz, Academic Medical Center, Amsterdam, The Netherlands. Creati-
nine clearance (Cr) overestimates true GFR because of tubular secretion
of creatinine (TSr). In patients with renal disease CCr/GFR can be as high
as 2. Cimetidine inhibits TSçr, without influencing GFR, thereby reducing
the overestimation of GFR. When standard Cr is measured, an important
error may also be introduced by inaccurate collection of urine. To
overcome this, C'r can be estimated from plasma creatinine, using the
Cockcroft and Gault formula (Ceock). We studied 19 patients with various
renal diseases and plasma creatinine <180 j.tmol/liter (range 57—179).
Proteinuria ranged from 0.02—8.4 g/24 hr (mean 2.96). We excluded
patients with a Quetelet index (bw/l2) >30 or <15. During the 24 hours
before GFR and creatinine determination the patients ingested orally 3 x
800 mg cimetidine. True GFR was measured as standard clearance using
continuous infusion of 1125-lothalamate (C1125). Plasma creatinine concen-
trations were assayed by the enzymatic PAP reaction, creatinine in the
urine by a modified Jaffé reaction. Plasma creatinine remained stable
during the 6 hour period of GFR measurement, indicating that a new
steady state was attained. The mean (±sEM) ratio of C0 to true GFR
decreased from 1.28 (±0.049) before to 0.98 (±0.025) after administration
of cimetidine (P < 0.001). Expressed as ml/min/1.73 m2 the mean (±sD)
difference from Cc0k to true GFR was 15.46 (±9.23) before and —2.51
(± 7.07) after cimetidine. After cimetidine, the estimation of true GFR by
CcOk was as good as the estimation of GFR, obtained from two 2 hour
creatinine clearances with urine collection (P > 0.05). Two patients had
incomplete inhibition of TScr (Cr/Ci125 1.21 and 1.12, respectively). These
2 patients had relatively low plasma cimetidine to creatinine ratios which
suggests that the dose of cimetidine might have been insufficient. Conclu-
sion: After cimetidine administration the Cockcroft and Gault formula
more closely approaches true GFR, provided that the patient's Quetelet
index is <30 >15. Therefore, it may be a useful method in the outpatient
control of patients with renal disease and normal or moderately impaired
renal function.
Steroid responsive human immunodeficiency virus associated nephrop-
athy (HIVAN). RH. Kauffmann, RB. Sic, iA. Bnujn, Leyenburg Hospital,
the Hague, and University Hospital Leiden, Leiden, The Netherlands. A
beneficial effect of prednisone in HIVAN has not been noted before. This
report describes two patients with HI VAN, dysphagia and elevated liver
enzyme levels who showed improvement with prednisone therapy. The
first patient (a 34 year-old black male) was found to have renal insuffi-
ciency (serum creatinine 220 jmol/liter, ereatinine clearance 40 mI/mm),
hypoproteinemia (protein 46 and albumin 21 g/liter), and proteinuria (4 g
protein/24 hr urine) without urinary cells. AIDS was diagnosed 3 months
previous due to a pneumocystis carinii pneumonia and HIV-l seroposi-
tivity; maintenance therapy with cotrimoxazol was given. He complained
of dysphagia and weight loss. Blood pressure was 135/80 mm Hg and
edema was absent. The SGOT was 74, SGPT 46, LDT-I 567, GOT 246 and
alkaline phosphatase 205 U/liter. His CD4 cell count was 30/mm3 and HIV
p24 Ag was not detected. A liver biopsy showed steatosis and scanty
infiltrates of mononuclear cells. The renal biopsy findings were compatible
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with HI VAN showing focal segmental and global sclerosis, glomerular tuft
collapse and swelling of glomerular and epithelial cells with hyaline drops
on light microscopy and tuhuloreticular structures in the endothelial
cytoplasm on electron microscopy. Cotrimoxazol was discontinued and
prednisone 60 mg/day was started. The serum creatinine fell to 120
rmol/liter, the albumin rose to 30 g/liter and the liver function tests
became normal after 3 weeks of prednisone. After 8 weeks at a prednisone
dose of 30 mg/day the creatinine was 90 rmol/liter. At that time he died
of small bowel obstruction due to Kaposi sarcoma. The second patient (a
27 year-old black male, HIV-1 seropositive for 3 years) complained of
dysphagia, 10 kg weight loss, and fever. He used cotrimoxazol 480 mg and
nevaripine 400 mg/day. Blood pressure was 110/75 mm Hg and edema was
absent. Serum ereatinine was 250 rmol/liter, rising to 400 rmol/liter after
10 days, protein was 76 g/liter, and albumin 27 g/liter, decreasing to 21
g/liter. Liver enzyme levels were raised: SGOT 108, SGPT 102, LDH 394,
GGT 730 and alkaline phosphatase 175 U/liter. His CD4 cells were
170/mm3 and HIVp24 Ag was detectable. A liver biopsy showed moderate
steatosis. The renal biopsy showed minimal glomerular sclerosis, swelling
and proliferation of visceral epithelial cells with hyaline droplets and
dilated tubuli containing proteinaceous casts on light microscopy and
endothelial tubuloreticular cytoplasmic structures on electron microscopy,
as in HI VAN. After treatment with prednisone, 60mg/day for 3 weeks, the
serum creatinine decreased to 170 rmol/liter, the albumin rose to 32
gJliter, and the liver function tests became normal except for the GGT.
After 3 months the serum creatinine was 140 .rmol/liter at a dose of 10 mg
prednisone/day. Thereafter he became dependent on a dose of 20 mg
prednisone to keep the creatinine level below 200 jrmol/liter. These two
cases of HIVAN accompanied by dysphagia and disturbed liver function
show that steroid therapy may improve renal function in HIVAN.
Prognostic methods for mortality of intensive care (IC) patients with
acute renal failure (ARF). CE. Douma, W.K Redekop, J.H.P. van der
Meulen, R. W van Olden, J. Haeck, D. G. Struijk, and R. T Krediet, Academic
Medical Center, Amsterdam, The Netherlands. Mortality of IC patients with
ARF is between 60 and 80% and has not changed over the years. The aim
of this retrospective study was to evaluate prognostic methods for
mortality in these patients. Prognostic information may be useful for
clinical decision making on the initiation of dialysis treatment. Of the 308
consecutive patients from 1985 to 1993 who were treated with dialysis for
ARF in IC, 273 were included, and 35 patients (11%) were excluded
because of incomplete data. Eight general prognostic methods and 4
methods, especially made for mortality prediction of patients with ARF,
were used to calculate a score or mortality risk for each patient. The
general methods were: APACHE II, Simplified Acute Physiology Score
(SAPS), SAPS.Reduced (SAPS.R), SAPS.Extended (SAPS.E), Mortality
Prediction Model (MPM), Sickness Scoring (SS), System Outcome Score
(SOS), and Multiple Organ System Failure (MOSF). The ARF specific
methods were described by the groups of Liano, Schaefer, Lohr and
Rasmussen. After ranking for predicted mortality risk, patients were
divided into 5 equally sized groups with increasing score or mortality risk
(I—V). Predicted (PM) and observed mortality (OM) in these groups was
calculated. Another way to compare methods is the Receiver Operating
Characteristic (ROC) curve. The overall mortality was 78%. The PM of
group I with the APACHE II was 14%, the OM was 76%, for group V the
PM was 70% and the OM 87%. APACHE II underestimated the
mortality. Furthermore, the difference in OM between patients with low
(group I) or high (group V) predicted risk was very small. The predictive
power of the MPM was somewhat higher: group I PM 4%, OM 61% and
group V PM 66%, OM 89%. The SAPS.R PM in group I was 22% and
OM 81%, in group V PM was 96% and OM 76%. SAPS.E: group I PM
18% and OM 63%, group V PM 73% and OM 77%. After calculation the
score of Liano the OM in group I was 61% and in group V 94%. The
remaining models showed mediocre performance. Only the method of
Schaefer overestimated mortality: PM in group I was 88% and OM 63%,
in group V PM 96% and OM 90%. The patient group of this study was
most comparable with our patient group: IC patients with acute dialysis
because of ARF. The areas under the ROC curves represent the predic-
tive power of a method. They vary from 0.50 (SAPS.R) to 0.70 (MPM). In
the part of the curve with the low false positive rate the contribution of all
methods to prediction was low. Conclusion: General prognostic methods
underestimate mortality of IC patients with ARF and the prognostic
power of these methods is low. The prognostic methods especially made
for patients with ARF give no better results. Therefore, none of these
methods can be used for clinical decision making in IC patients with ARF.
The micturition of the conscious rat: Reliability of urine collection
without catheterization. M. Haas, CA. Kluppel, D.KF. Meijer, P.E. defong,
F. Moolenaar, and D. de Zeeuw, GIDS, University Groningen, Groningen,
The Netherlands. Accurate urine sampling in conscious rats is often
performed by invasive techniques with risk of infection. We tested the
feasibility of timed urine collection, using a computerized sample collector
in freely-moving spontaneously-voiding rats. The table shows that the
frequency of urine voiding (Utrcq) and the sample volume (U01) varied
considerably over a S day period with a high individual variation coefficient
(VC) per day. Since urinary creatinine excretion (UcrV, HPLC measured)
was far from its expected constancy over the day, the data suggest
incomplete bladder voiding. Forced diuresis induced by infusion (0.45%
NaCL/2.5% glucose 2 mI/br) failed to reduce this biasing phenomenon. In
both situations, with and without a forced diuresis, the large variation only
allows detection of intervention-induced changes in diuresis and natriure-
sis of over 100%.
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Interestingly, both the urinary flow (UV) and sodium excretion (UNV),
closely correlated to the creatinine excretion (r = 0.85 and 0.70 without
infusion, r = 0.88 and 0.82 with infusion for UV and respectively;
all P < 0.0005). Thus, as shown in the table, creatinine correction of UV
and UaV (UV-c and UNaV-c) resulted in a considerable reduction of the
VC and 95% confidence interval (CI). Detection of 40% changes in both
parameters becomes possible. We conclude that bladder voiding is often
incomplete and/or the urgency to void is hardly related to the amount of
urine present in the bladder. In spite of the increased voiding volume and
frequency, constant infusion of NaCI/glucose does not result in a reduction
of the degree of fluctuation. Correction of such incomplete bladder
emptying is feasible using creatinine excretion data. It increases the
sensitivity of detecting intervention-induced changes in urinary water and
sodium excretion, and likely that of other urinary parameters.
Prevention of relapses of Wegener's granulomatosis by treatment with
trimethoprim-sulfamethoxazole. A multicenter placebo.controlled trial.
CA. Stegeman J. W Cohen Tervaert, P.E. de long, and C. G.M. Kallenberg,
Division of Clinical Immunology and Nephrology, University Hospital,
Groningen, The Netherlands. Wegener's granulomatosis is a frequently
relapsing form of systemic vasculitis associated with the presence of
anti-neutrophil cytoplasmic antibodies (ANCA). Infections are suggested
to trigger disease activity, a view supported by observations reporting
beneficial effects of treatment with trimethoprim-sulfamethoxazole (co-
trimoxazole). However, prospective controlled studies on the efficacy of
co-trimoxazole as a therapeutic or prophylactic agent in Wegener's
granulomatosis are lacking. We conducted a multi-center, prospective,
randomized, placebo-controlled study with co-trimoxazole 800/160 mg
hid, during 24 months in 81 patients with Wegener's granulomatosis to
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assess the efficacy of co-trimoxazole in preventing relapses. Relapses were
scored using predefined criteria. The number of infections was assessed
and serial determination of serum cANCA was performed. In 8 of 41
patients (19%) assigned to co-trimoxazole, treatment had to be stopped
prematurely due to side effects. Seven of the 41 patients assigned to
co-trimoxazole treatment relapsed during 24 months of follow-up as
compared to 16 of 40 patients assigned to placebo [relative risk 0.40 (95%
percent confidence interval, 0.17 to 0.98), logrank test]. A reduction in the
number of respiratory (P = 0.0046) and non-respiratory infections (P =
0.047) was found with co-trimoxazole treatment as compared to placebo.
No significant differences in cANCA titers between the groups were
found. Proportional-hazards regression analysis identified treatment with
co-trimoxazole [adjusted relative risk 0.32 (95% CI 0.13 to 0.79)] and a
positive cANCA test at the start of the study [adjusted relative risk 2.89
(95% CI 1.12 to 7.45)1 as independent risk factors for relapse. In
conclusion, prolonged treatment with co-trimoxazole leads to a reduced
incidence of relapses in patients with Wegener's granulomatosis in whom
remission is induced with cyclophosphamide and prednisolone.
Improved ultrafiltration in CCPD patients using a glucose polymer
(GP) instead of glucose (C) as last bag. N. Posthuma, P.M ter Wee, AIM.
Donker, P.L. Oe, and H.A. Verbmgh, Department of Nephrology, Free
University Hospital Amsterdam and Department of Clinical Microbiology,
University Hospital Rotterdam, Rotterdam, The Netherlands. Continuous
peritoneal dialysis is associated with an increased risk of peritonitis and
changes in the peritoneal membrane which can, in turn, lead to loss of
ultrafiltration (UF) capacity. These disadvantages are long-term compli-
cations related to the use of hyperosmolar glucose solutions with a lack of
biocompatibility. Recently, we started a randomized prospective study on
the effect of glucose and glucose polymer (Dextrin 20; molecular weight
20,000 kD; 282 mOsm/kg) in automated peritoneal dialysis (APD) when
used for the long daytime dwell. Of the 30 patients currently entered, 13
had a negative drain 0 at the start of the study. Because of this negative
ultrafiltration during the daytime dwell, the administered volume had
been reduced in several patients and some patients even had a "dry






0 —435 —409 +754 +977
3 —347 +249 +837 +1311
6 —335 +233 +537 +1278
The six patients treated with glucose solutions manifested a persistently
negative drain 0 after six months (Table). In contrast drain 0 became
positive in 6 of 7 patients treated with the GP solution. In addition, in
these patients the total UF improved. Thus, in all patients treated with the
GP solution the CCPD treatment schedule could be adapted resulting in
a reduction of the glucose concentration during the nightly exchanges or
in the number of exchanges (as can be seen, because the drain 0-UF rose
ml and the total UF 300—330 ml). As a result, the increase in allowed
daily fluid intake together with the adapted treatment schedule improved
the patients' subjective well-being, without complaints about the GP
solution itself. In conclusion, the use of a Dextrin 20 solution enhances
ultrafiltration, thus facilitating a less rigid restriction of daily fluid intake
and/or treatment schedule resulting in an improved general well-being.
Balloon-expandable stent implantation in patients with renovascular
hypertension due to atherosclerotic ostial renal artery stenosis. P.J. G. vd
Ven, J.J. Beutler, G.G. Geyskes, A.J. Woittiez, F.J.A. Beck, WP. Th.M. Mali,
and HA. Koomans, Departments of Nephrology & Hypertension and Radi-
ology, University Hospital Utrecht, Utrecht, The Netherlands. PTRA of
atherosclerotic ostial renal artery stenosis (RAS) is known for its high
restenosis rate. We implanted a balloon-expandable stent (Palmaz) in 23
consecutive patients with renovascular hypertension due to atherosclerotic
ostial RAS: 4 with unilateral stenosis, 7 with bilateral stenosis, and 12 with
one-sided stenosis and an occluded contralateral renal artery. Mean BP
was 190 31/105 11 mm Hg while on diverse medication. All patients
had a positive captopril renography and/or a rise in serum creatinine
during ACE-inhibition. Of the patients with bilateral RAS, 3 had bilateral
ostial RAS and received bilateral stents. Thus, a total of 26 stents were
placed. Angiographic results: Initial success rate was 96% (25/26 arteries).
Follow-up angiography (N = 13, 15 arteries, mean 8 months, range 2—16)
revealed significant restenosis in 13% (2/15). Clinical results: In the 12
patients with an occluded small contralateral kidney, ACE inhibition
(ACEi) for BP control prior to stenting caused renal failure (median
creatinine 249 jimol/liter, range 145—1,200). After unilateral stent place-
ment (occluded kidney untouched) reasonable BP control (median BP
160/88 mm Hg, range 115—210/70—115) with ACEi became possible with
better renal function (creatinine 152 jrmol/liter, range 102—800). In the
other ii patients the median BP improved from 200/105 to 170/90mm Hg,
while plasma creatinine remained unchanged (median 126 smol/liter,
range 90—480, before, and 133 imol/liter, range 75—605, after). Major
complications occurred in 13% (3/23); renal artery dissection (1), choles-
terol embolism causing decreased renal function (2), and toe amputation
(1). In conclusion, these preliminary data show that atherosclerotic ostial
RAS can be treated by balloon-expandable vascular stent implantation
with satisfactory technical as well as clinical results: improvement of blood
pressure control while renal function is preserved. In view of the severity
of disease, the complications seem acceptable.
Evaluation of the Banif criteria for the histologic diagnosis of rejection
in renal allograft biopsies. Ph.M.M. Dooper, A.J. Hoitsma, R.A.P. Koene,
and M.J.J. T. Bogman, Departments of Pathology and Medicine, University
Hospital Nzjmegen, Nijmegen, The Netherlands. To assess the value of the
recently developed Banif working classification of kidney transplant
pathology for clinical practice, we compared retrospectively and blindly
scored histological diagnoses, according to the Banif criteria, with the final
clinical diagnoses in 210 renal allograft biopsies taken over a three year
period in 145 patients with signs of graft dysfunction or proteinuria. The
final clinical diagnoses were divided into five categories: acute rejection
(AR), probable AR (prAR), equivocal (Eq), chronic rejection (CR), and
no rejection (no R).
Banif diagnosis N
Clinical diagnosis
AR prAR Eq CR no R
Borderline changes
AR 38 8 6 0 8 16
GrI 30 14 2 2 2 10
GrIl/Ill 118 85 13 7 5 8
CR/CsA/ATN/a.o. 24 1 1 0 9 13
Total 210 108 22 9 24 47
When the clinical diagnoses AR and probable AR are taken together and
considered as clinical AR, the Banif criteria pointed to a correct diagnosis
in 114 of the 130 rejection episodes, and in 46 of 80 cases without AR (that
is, the total of cases with clinical diagnoses Eq, CR or no R). We conclude
that the Banif classification system can serve as an acceptable guideline for
a standardized histologic diagnosis of renal allograft rejection. A major
shortcoming of the schema, however, is its overestimation of the diagnosis
of acute rejection. Furthermore, 14 of the 38 biopsies with borderline
changes correlated with clinical AR. Thus, the advice in the Banif
classification that "borderline changes" are insufficient to justify anti-
rejection treatment must be interpreted with caution.
Administration of OKT3 via continuous infusion attenuates first-dose
side-effects. S. Buysmann, CE. Hack, F.N.J. van Diepen, J.M. Wilmink, S.
Surachno, and RIM. ten Berge, Renal Transplant Unit and Clinical
Immunology Unit, Department of internal Medicine, Academic Medical
Centre and Laboratory for Experimental and Clinical Immunology, Univer-
sity of Amsterdam, Amsterdam, The Netherlands. The murine anti-CD3
monoclonal antibody OKT3 has proven its efficacy in prevention and
treatment of allograft rejection. However, extensive use of OKT3 is
limited by the clinical side effects which occur following the first dose
administered as a bolos injection. These side effects have been attributed
to a systemic release of cytokines, that is TNFs (Tumor Necrosis Factor
a), IFNy (Interferon y), IL-2 (Interleukin-2), -3, and -6 and to immediate
activation of complement and neutrophilic granulocytes. The latter is held
mainly responsible for the early respiratory symptoms. Complement
activation products themselves may induce release of cytokines, thus
potentiating their noxious activities. Since complement activation occurs
in a dose-dependent way, we investigated whether administration of
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OKT3 as a continuous infusion during 2 hours could diminish the rapid
complement activation and consequently the complement induced cyto-
kine release and activation of neutrophils. In addition, we monitored
whether a reduction of side effects occurred. Therefore, 18 renal allograft
recipients were studied, who received 5 mg OKT3 prophylactically, either
as a continuous infusion for 2 hours (N = 9), or as a single intravenous
bolus injection (N = 9). Patients treated with continuous inftision experi-
enced fewer side effects (score based on presence/absence of fever, chills,
dyspnea, headache, diarrhea, nausea or vomiting, P = 0.007) and had a
lower paracetamol consumption during the whole 10 day course. Peak
levels of complement activation products C3a-desarg and C3b/c were
significantly higher in the bolus group (22.34 2.78, respectively 122.11
16.05 nmol/liter) as compared to the continuous infusion group (9.82
2.02 resp. 66.50 18.86 nmol/l; P = 0.007 respectively, P = 0.005,
Mann-Whitney test). In contrast no significant differences were observed
between both groups in plasma cytokine levels (TNFa, IL-6, and IL-8) nor
in activation of neutrophils as measured by plasma levels of eiastase and
lactoferrin. Conclusion: Administration of the first dose OKT3 as a
continuous infusion for 2 hours induces fewer side effects as compared to
bolus administration, the reduction of which is probably due to a lower
degree of complement activation. Thus, in addition to cytokines, comple-
ment activation products seem to be pathogenic not only in the dyspnea
occurring immediately after the first dose, but also in the side effects
occurring later on.
Release of secretory phospholipase A2 during OKT3 treatment and
possible implications for renal function. P.C. Wever, R. W. Roest, A.M.
Wolbink-Kamp, G.J. Wolbink, J.J. Weening, C.E. Hack, and R.J.M. ten
Berge, Academic Medical Center, Departments of Internal Medicine and
Pathology, and Central Laboratoiy of the Netherlands Red Cross Blood
Transfusion Service, Amsterdam, The Netherlands. OKT3, a murine mono-
clonal antibody of the IgG2a class directed against the CD3 molecule on
T lymphocytes, is used in the prophylaxis and treatment of acute renal
allograft rejection. Its use is followed by a transient nephrotoxic effect as
reflected by an early rise in serum creatinine levels. An increase in
circulating group II secretory phospholipase A2 (sPLA2) levels might
account for this nephrotoxic effect, since sPLA2 induces the biosynthesis of
prostaglandins (PGs) and platelet-activating factor, which are known
vasoactive lipid mediators influencing glomerular hemodynamics and
renal function. We retrospectively studied plasma levels of sPLA, in 15
renal allograft recipients receiving OKT3 for the treatment of acute
cellular rejection (ACR) and related these levels to circulating levels of
tumor necrosis factor-a (TNF-a), interleukin 6 (IL-6) and C-reactive
protein (CRP) and to renal function. As a control group, we studied 15
renal allograft recipients receiving methylprednisolone (MPNS) for the
treatment of ACR. In the OKT3 treated group sPLA2 levels increased
from 517 223 ng/ml to peak levels of 2091 693 ng/ml at 48 hours after
the first drug administration (mean SEM, P < 0.05). The rise in sPLA2
levels was preceded by significant increases in TNF-a and IL-6 levels and
accompanied by a significant increase in CRP levels. Creatinine levels
increased up to 127 21% compared to pretreatment levels at 72 hours
after initiation of treatment (mean SEM, P < 0.05), after which a gradual
improvement in renal function was observed. In the MPNS treated group
no increases in sPLA2, TNF-cs, IL-6, CRP and creatinine levels were
found. Here, we show that administration of OKT3 results in cytokine-
induced release of sPLA2 and that peak levels of sPLA2 are associated
with increases in creatinine levels. Currently, we are prospectively studying
the urinary excretion of PGs after OKT3 administration in relation to
circulating sPLA2 levels and renal function.
Acute renal allograft rejection is associated with increased excretion of
monocyte chemoattractant protein.!. W. Prodjosudjadi, MR. Daha, J.S.J.
Gerritsma, K W Flonjn, J.N.M. Barendregt, J.A. Bniijn, F.J. van der Woude,
and L.A. van Es, Department of Nephrology and Pathology, University
Hospital Leiden, Leiden, The Netherlands. There is a strong correlation
between peritubular infiltration of monocytes and acute renal allograft
rejection. It is not clear which factors regulate the influx of monocytes, but
activation fragments of complement, adhesion molecules, and monocyte
chemoattractant protein-i (MCP-1) have been implicated. In the present
study we have investigated the levels of MCP-1 in serum and the excretion
of MCP-1 in urine of transplant patients with (N = 9) and without (N =
11) acute renal allograft rejection, represented by Rj and NRj groups
respectively. MCP-1 staining of renal biopsies from the Rj group was
performed. As controls, normal subjects (N = 9) and patients with
ADPKD (N = 14)were included. Urinary excretion of MCP-i as assessed
by radioimmunoassay was significantly higher in the Rj group (938.7
586.9 ng/mmol Cr) than in the NRj group (199.7 122.4 ng/mmol Cr), the
ADPKD group (118.9 32.2 ng/mmol Cr), and the normal control group
(53.5 13.3 ng/mmol Cr). However, there was no significant difference in
the levels of MCP-i in serum between the various groups. The molecular
weight of MCP-1 obtained from urine of patients with acute rejection was
13 and 11 kD, and both sizes were chemotactically active for monocytes.
The intensity of MCP-1 staining on tubular epithelial cells from biopsies of
renal allograft rejection was significantly increased as compared to the
results from pretransplant biopsies. Seven out of 9 renal allograft biopsies
showed an increase of more than 50% of total peritubular area, in the
percentage of peritubular CDi4 cells, as a marker for macrophages. In
conclusion, we found that urinary excretion of MCP-1 is increased during
acute renal transplant rejection. Serum levels of MCP-1 are not different
between NRj, Rj, and normal controls. The observation that interstitial
infiltration of macrophages is increased during a rejection process, com-
bined with our previous findings that tubular epithelial cells produce
MCP-1, suggest that local production of MCP-i by tubular epithelial cells
may be responsible, in part, for the recruitment of macrophages. In
addition, urinary MCP-1 may therefore be derived from inflamed tubular
epithelial cells or from infiltrating macrophages. Furthermore, in combi-
nation with other parameters, urinary excretion of MCP-1 seems to be a
suitable marker for renal allograft rejection.
